Skip to main content
Fig. 5 | Cancer Nanotechnology

Fig. 5

From: HB5 aptamer-tagged graphene oxide for co-delivery of doxorubicin and silibinin, and highly effective combination therapy in breast cancer

Fig. 5Fig. 5

A Cellular internalization of Apt-cGO into MCF-10A, SK-BR-3, and MCF-7 cells. B The quantification of cellular uptake capacity of Apt-cGO by calculating the CTCF. C, D The cellular internalization of DOX and Sili after the cell incubation with free DOX, free Sili, free DOX + free Sili, and completed NPs (Apt-cGO-DOX-Sili) for 3 h in SK-BR-3 cells (C) and MCF-7 cells (D). E The quantification of cellular uptake capacity of free DOX, free Sili, free DOX + free Sili, and completed NPs (Apt-cGO-DOX-Sili) by calculating the CTCF. The CTCF was calculated using Image J software. Data are provided as mean ± SD (n = 3). cGO: carboxylated Graphene oxide; Apt: aptamer; DOX: doxorubicin; Sili: silibinin; CTCF: corrected total cell fluorescence

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us